)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Immix Biopharma
Immix Biopharma (IMMX) investor relations material
Immix Biopharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
NEXICART-2 enrollment completed at 45 patients; September data showed 40 complete responses (89%), with four MRD-negative patients awaiting CR status and potential to reach 44/45 (98%).
Launch preparation continued across commercial site activation, provider and payer engagement, manufacturing, and healthcare professional education.
Interim NEXICART-2 results were selected for an oral presentation at ASH 2026.
Financial highlights
Q3 2026 operating expenses were $15.9M, including $10.4M in R&D and $5.5M in G&A, versus $7.7M a year earlier; net loss was $13.9M versus $7.6M.
9M 2026 operating expenses were $39.2M versus $19.1M a year earlier; net loss was $35.6M versus $18.8M.
Interest income was $2.0M in Q3 and $3.6M in 9M 2026, versus $0.1M and $0.3M, respectively, a year earlier.
No product-sales revenue; Q3 basic and diluted loss per share was $0.19 versus $0.24, while 9M loss per share was $0.55 versus $0.61.
Outlook and guidance
Planned BLA submission is mid-2027; NEXICART-3 frontline trial initiation is planned for H1 2027.
Cash, cash equivalents, and marketable securities were expected to fund operations into mid-2028; the filing separately stated cash, cash equivalents, and short-term investments would fund operations for at least 12 months from its filing date.
NEXICART-2 interim data were scheduled for presentation at ASH on December 14, 2026; a presentation was also planned at the J.P. Morgan Healthcare Conference, January 11–14, 2027.
Expenses and operating losses are expected to rise as clinical programs expand; additional capital is expected to be needed beyond the stated runway.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Immix Biopharma
- NXC-201 achieved 89% CR in NEXICART-2, with Phase 3 planned for 1H 2027.IMMX
Investor presentation - NXC-201 achieved an 89% CR rate, with potential to reach 98% in AL amyloidosis.IMMXStudy result
- NXC-201 shows strong efficacy and safety in AL amyloidosis, with pivotal data and BLA submission ahead.IMMXMorgan Stanley 24th Annual Global Healthcare Conference
- NXC-201 delivers 95% complete response in relapsed/refractory AL amyloidosis, redefining outcomes.IMMXCorporate presentation
- NXC-201 achieved 95% complete response in relapsed/refractory AL amyloidosis with rapid, safe results.IMMXCorporate presentation
- NXC-201 Phase 2 showed 95% CR rate; $232M cash reserves support ongoing clinical expansion.IMMXQ2 2026
- NXC-201 delivers 95% complete response in relapsed/refractory AL amyloidosis with rapid, deep organ responses.IMMXCorporate presentation
- NXC-201 achieved a 95% complete response rate in relapsed/refractory AL amyloidosis.IMMXCorporate presentation
- Q1 2026 net loss rose to $10.1M as R&D spending increased; cash reserves remain strong.IMMXQ1 2026
Next Immix Biopharma earnings date
Q4 202625 Mar, 2027
Immix Biopharma
Next Immix Biopharma earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Immix Biopharma Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for cancer and inflammatory diseases. The company’s lead programs are based on its proprietary tissue-specific therapeutics platform, designed to deliver biologics and small molecules to specific tissues while minimizing systemic toxicity. Immix Biopharma conducts clinical trials for rare and hard-to-treat cancers, as well as immune-related conditions. The company is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.